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Pneumocystis is an opportunistic fungal respiratory pathogen that causes life-threatening pneumonia (Pcp) in patients
suﬀering from defects in cell-mediated immunity, including those with acquired immunodeﬁciency syndrome (AIDS) and
immunosuppression secondary to chemotherapy or organ transplantation. Despite major advances in health care, the mortality
associated with Pcp has changed little over the past 25 years. Pcp remains a leading cause of death among HIV infected patients,
with mortality rates of 50% or higher for patients developing severe Pcp. In addition, as more potent immunosuppressive
therapies are developed for chronic inﬂammatory diseases, more cases of Pcp are occurring in non-HIV patients and in previously
unreported clinical settings. These features highlight the importance of developing a better understanding of the pathogenesis of
this disease, and the need to search for new therapeutic strategies to improve the outcome of Pcp patients. Immune-mediated
inﬂammatory responses play an important role in the pathogenesis of Pcp, and may be even more signiﬁcant in determining
the outcome of Pcp than direct damage due to the organism itself. In this review we will summarize the immunopathogenic
mechanisms that contribute to Pcp-associated lung injury, and discuss the potential to target these pathways for adjunctive
immune modulation therapy for Pcp.
1. Potential Cellular Targets for
Immune Modulation
1.1. CD4+TC e l l s . T h eh o s t ’ si m m u n er e s p o n s ei so n eo ft h e
main pathogenic determinants of lung injury during Pcp
[1–7] and involves the interactions between immune cells
and soluble mediators such as cytokines and chemokines.
CD4+ T cell numbers and function determine the host
susceptibility to infection. Animal models of SCID, Rag1−/−,
Rag2−/− or, CD4+-T-cell-depleted mice directly demonstrate
the role of CD4+ T cells in resistance to Pneumocystis
infection[8,9].Inhumans,theimportanceofCD4+ Tcellsis
demonstrated by the clinical observation that Pcp occurs in
patients,of5yearsofageandolder,whenCD4+ Tc ellc ounts
fall below 200cells/mm3 [10].
Although CD4+ T cells are required for eﬀective host
defense against Pneumocystis infection, these cells also
contribute to immune-mediated lung injury during Pcp.
For example, Pneumocystis-infected SCID mice have very
little lung damage until the late stages of disease. However,
if these animals are immune reconstituted with congenic
splenocytes, an intense immune-mediated inﬂammatory
response consisting of CD4+ and CD8+ T cells is initiated,
causing substantially impaired lung function [7]. A similar
phenomenon occurs when AIDS patients receive antiretrovi-
ral therapy, or when steroids are tapered in cancer patients
receiving chemotherapy [11–13]. In patients, this clinical
manifestation of Pcp is termed immune reconstitution
inﬂammatory syndrome (IRIS).
In murine models of IRIS, CD4+ Tc e l l sa r em o s ta b u n -
dant during the acute stage of disease that coincides with
the development of impaired pulmonary physiology and
organism clearance. The severity of IRIS is closely related to
theextentofCD4+ Tcellrecovery,andthesecellsarethought
to directly mediate the pathogenic process. Therefore, anti-
CD3 has been explored as a possible adjunctive therapy for2 Interdisciplinary Perspectives on Infectious Diseases
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Figure 1: Changes in the body weight and survival rate of experimental mice. (a) Percent loss of body weights (compared with the peak
weight) for diﬀerent groups of experimental mice is plotted against the days after reconstitution. Each data point represents arithmetic
mean ± SEM. (b) The Kaplan-Meier plot of survival analysis. Survival data of mice pooled from three experiments were summarized in the
ﬁgure. Proportion of survivors versus time (days after treatment start) are plotted. To make the analysis more conservative, the mice that
were sacriﬁced for lung function and inﬂammatory measurements were assumed to survive until the last day of the experiment. Kaplan-
Meier Log Rank Test was performed using Sigma-Stat 3.5, which was found to be signiﬁcant (P<0.001) (Copyright 2010, The American
Association of Immunologists, Inc.)
the treatment of Pcp. The pan-T-cell antibody anti-CD3
was used in a murine model of Pcp-related IRIS to assess
whether it was eﬀective for reducing the severity of Pcp even
if administered after the onset of disease. Mice that received
anti-CD3 antibody exhibited a rapid and dramatic reduction
in Pcp-associated inﬂammatory lung injury within 1 week
after beginning treatment, and a signiﬁcant enhancement
of survival rate compared with mice receiving control
antibody (Figure 1). The physiologic improvement in anti-
CD3-treatedmicewasassociatedwithasigniﬁcantlyreduced
CD4+ and CD8+ T cell inﬂux into the lungs. Combining
anti-CD3 with trimethoprim-sulfamethoxazole treatment
allowed for eradication of the organism as well as control of
the associated inﬂammatory injury [14]. These data suggest
that monoclonal antibody-mediated disruption of T cell
function may represent a speciﬁc and eﬀective adjunctive
therapy to rapidly reverse the ongoing pathologic immune
response occurring during active Pcp. There is extensive
clinical experience with the use of anti-CD3 in patients. This
experience could provide the starting point for developing a
clinical trial of adjunctive therapy for Pcp.
1.2. CD8+ TC e l l s .In contrast to CD4+ T cells, CD8+ T
cells are more abundant during the resolution phase of IRIS
[7, 15], and separate reports by Bhagwat et al. and Swain et
al. reported that CD8+ T cells can exert anti-inﬂammatory
function during Pcp by controlling the intensity of CD4+
T-cell-mediated immune response [16, 17]. If immune-
reconstituted mice are depleted of CD8+ T cells, they are
able to clear the Pneumocystis infection but develop severe
inﬂammatory disease, with increased IFN-γ production
a n dap r o l o n g e dC D 4 + T cell response compared to fully
reconstituted mice. This is likely due to the loss of suppressor
CD8+ T cell functions [16]. Most often, however, Pcp occurs
in the setting of persistently low or poorly functional CD4+
T cells. In this setting, CD8+ T cells contribute to the
inﬂammatory lung injury [7, 18]. In the absence of CD4+ T
cells, CD8+ T cells do not clear the organism but do produce
an ineﬀective immune response that results in signiﬁcant
lung damage and respiratory impairment [16, 18]. CD8+-
T-cells mediated inﬂammation and pulmonary dysfunction
arecharacterizedbyincreasedlungproductionofTNF-αand
chemokines and altered surfactant homeostasis.
While our studies have documented the pathologic role
of CD8+ T cells during Pcp, these cells may also have
beneﬁt under certain conditions. Kolls et al. demonstrated
that adenoviral-mediated delivery of IFN-γ to the lungs
of CD4+-T-cell-depleted mice resulted in enhanced host
defense against Pneumocystis infection. The IFN-γ-mediated
eﬀects were dependent upon the generation of T cytotoxic-1
CD8+ Tc e l l sa n dG M - C S F[ 19–21]. Together, these studies
suggest that the development of therapies to modulate CD8+
Tcellphenotypeandfunctioncouldhavebeneﬁcialeﬀectsof
Pneumocystis clearance and immunopathogenesis.
1.3. Regulatory T Cells. Regulatory T cells (Treg) are a subset
of T cells expressing CD4, CD25, and Foxp3. These cells
maintain immunological tolerance to “self” and regulate
the immune response to infectious organisms. Treg cells
represent an important mechanism for the maintenance ofInterdisciplinary Perspectives on Infectious Diseases 3
immune homeostasis in the lungs [22], and recent studies
haveexploredtheroleofTregsduringPcp.Horietal.showed
that adoptive transfer of CD4+CD25+ T cells attenuated
lung inﬂammation in Pneumocystis-infected SCID mice
[23]. In a later study, Mckinley et al. found that adoptive
transfer of CD4+CD25+ T cells to mice with Pcp-related
IRIS reduced pulmonary inﬂammation and lung injury [24].
These data suggest that CD4+CD25+ T cells control the
immune response during Pneumocystis, and modulation of
the number and function of this cell population could be a
potential therapeutic choice for Pcp.
1.4. Neutrophils. Clinical studies in AIDS patients and other
immunosuppressed patients with Pcp suggest that disease
severity is directly proportional to both neutrophil and inter-
leukin 8 levels in the lung [1–3, 5]. The association between
lung injury and neutrophil inﬂux has also been noted in
mouse models of Pcp. In the studies by Swain et al., the role
ofneutrophilsinlungdamagewasstudiedinseveraldiﬀerent
mouse models with a variety of neutrophil defects. These
included: gp91 knockout mice in which production of reac-
tive oxygen species (ROS) by neutrophils is greatly reduced
gp91- and inducible-nitric-oxide-synthase- (iNOS-) double-
knockout mice in which both ROS and NO production is
greatly reduced; chemokine CXCR2 receptor knockout mice
inwhichneutrophilrecruitmenttositesofinfectionisgreatly
reduced; ﬁnally wild-type mice depleted of neutrophils
by systemic administration of antineutrophil monoclonal
antibody. In each case, despite impaired neutrophil function
orreducednumbersinthelung,thephysiologicalparameters
of lung injury or the Pneumocystis burden were the same
as measured in mice with fully functional neutrophils [25].
This study suggested that neutrophil inﬂux into the lung
is an indicator of disease severity rather than the direct
causeofthelunginjury.Therefore,modulationofneutrophil
recruitment or function seems unlikely to be eﬀective for the
treatment of the immune consequences of Pcp.
1.5. Alveolar Macrophages. Alveolar macrophages (AMs) are
a critical component of innate and adaptive immunity in the
lungs and are important for host defense against Pneumo-
cystis infection. Lebron et al. reported that Pneumocystis β-
glucan stimulates TLR4-independent NF-κBa c t i v a t i o ni n
a murine macrophage cell line by using a receptor other
than TLR4 which is required for the macrophage TNF-α
response to LPS [26]. Furthermore, Steele et al. reported
that murine alveolar macrophages recognize Pneumocystis
β-glucan through Dectin-1 pattern recognition molecule,
and that, this interaction is required for secretion of MIP-
2 and nonopsonic phagocytosis [27]. A more recent study
by Zhang et al. demonstrated that NF-κBi si n v o l v e di nI L - 8
production by AMs in the response to rat Pneumocystis.I n
addition, the mannose receptor is required for the activation
of NF-κB and IL-8 secretion [28]. Studies of TLR2-deﬁcient
mice revealed that TLR2 is critical for AM inﬂammatory
responses to Pneumocystis. These data suggest that AMs
are important inﬂammatory mediators during Pneumocystis
infection and that modulation of AM function is a potential
strategy to regulate the lung inﬂammatory response during
Pcp. Lasbury et al. reported that AM apoptosis during Pcp
contributes to the weakened immune status in the lung
and promotes the progression of disease [29]. Blockade
of AM apoptosis with caspase inhibitors enhanced the
clearance of Pneumocystis organisms in rodent models of
Pcp, suggesting that modulation of AM survival could
represent a therapeutic approach to treatment.
Much of the recent work related to macrophage biology
has focused on the generation and function of distinct
polarized,macrophagesubsets.Duringtheadaptiveimmune
response macrophages can become activated by antigen-
speciﬁc TH cells, and TH-derived signals induce distinct
activation programs in macrophages that are directly related
to polarity of the TH response [30, 31]. Classically activated
macrophages (CAMs or M1) are induced by the TH1
cytokines IFN-γ and TNF-α, and they express high levels
of proinﬂammatory and host defense molecules, including
iNOS, ROS, TNF-α, IL-1, IL-12, MHC II, and Cox-2.
CAMs are critical for host defense against intracellular
pathogens, but also contribute to the immunopathology
associated with chronic inﬂammatory diseases. In contrast,
alternatively activated macrophages (AAMs or M2) are
induced by the TH2 cytokines IL-4 and IL-13, and counter-
balance the proinﬂammatory CAM response. AAMs express
arginase-1, CD163, MR, TGF-β, IL-10, and IL-1 receptor
antagonist. AAMs are important for host defense against
parasitic infections; they have high phagocytic activity,
produce anti-inﬂammatory cytokines, and are important
for tissue repair. Importantly, AAMs can actively down-
regulate CAM-mediated proinﬂammatory responses. We
have recently found a striking relationship between host
defense, immunopathogenesis, and AM phenotype in a
mouse model of Pcp-related IRIS. The immunomodulatory
drug Sulfasalazine (SSZ) dramatically reduced Pcp-related
immunopathogenesis while also enhancing macrophage-
mediated phagocytic clearance of Pneumocystis organisms
from the lung (Figure 2)[ 32]. Importantly, the beneﬁcial
eﬀects of SSZ on immunopathogenesis and phagocytosis
were associated with the alternative activation of lung
macrophages (M2). This eﬀect may either be the result of
SSZ promoting a Th2 response environment in the lung, or
the result of SSZ exerting direct eﬀects on AMs. This study
suggests that alternatively activated macrophages are better
suited to deal with Pneumocystis infection in a less inﬂam-
matory manner than classically activated macrophages. A
recent report by Nelson et al. corroborated our ﬁnding by
demonstrating that M2-polarized macrophages eﬃciently
kill Pneumocystis organisms [33] .T h e s es t u d i e ss u g g e s t
that AMs not only are important for host defense against
Pneumocystis infection, but also contribute to the lung
inﬂammatory response during Pcp. Thus, control of AM
phenotype with pharmacologic agents, such as SSZ, might
be beneﬁcial in the treatment of Pcp.
1.6. Alveolar Epithelial Cells (AECs). Lung epithelial cells are
the predominant cell types for Pneumocystis to interface with
in the lung. Importantly, these cells are uniquely positioned4 Interdisciplinary Perspectives on Infectious Diseases










Figure 2: SSZ enhances CD4+-T-cell-dependent AM phagocytosis
of Pc. BAL cells were collected from PBS- and SSZ-treated mice
at day 18 (17/18) post-reconstitution. Cells were stained with anti-
bodies speciﬁc for CD11c (green) and Pneumocystis (red). Imaging
ﬂow cytometry was used to measure Pneumocystis internalization
by AMs. Representative images of bright ﬁeld (BF), CD11c, Pc, and
merged CD11c/Pc are shown for PBS- (a) or SSZ-treated (b) mice
following immune reconstitution.
in close proximity to blood vessels whichcarry inﬂammatory
andimmunecellsthatmediatethehostresponsetoinfection.
Studies of the immunopathogenesis of Pcp have examined
the response of AEC to Pneumocystis. Studies with both
AEC cell lines and primary cultures of AECs found that
they produce inﬂammatory cytokines such as IL-6 and IL-
8 and chemokines such as MCP-1 and MIP-2 in the response
to Pneumocystis surface β-glucan or live organisms [34–
36]. MCP-1, a chemokine involved in lung inﬂammatory
responses and lung epithelial cell repair, is produced by
Pneumocystis-stimulated AECs through a MAPK- and NF-
κB-dependent mechanism [37]. Furthermore, in vivo studies
using TNF receptor deﬁcient bone marrow chimera mice
determined that TNF signaling in lung parenchymal cells
is important for the inﬂammatory lung injury during
Pcp [38]. These studies suggest that AECs are important
inﬂammatory mediators during Pcp, and that modulation
of AEC-speciﬁc responses could help reduce Pcp-associated
immunopathogenesis.
2. PotentialMolecular Targets for Therapeutic
Immunomodulation of Pcp
Currently, high-dose corticosteroid treatment is utilized as
adjunctive therapy for Pcp with the intent of reducing the
pathological immune response [39, 40]. However, a study by
Walzer et al. found that survival rates of patients with Pcp in
the period before steroids were routinely used as adjunctive
therapy was not dramatically diﬀerent from survival rates
of patients in the poststeroids era [41]. Although steroids
are eﬀective at controlling the proinﬂammatory responses
of immune cells, they also have proapoptotic consequences
for structural cells of the lung, including epithelial cells.
It has even been suggested that the proapoptotic eﬀect of
steroidsonlung epithelial cellscontributestotheremodeling
associated with asthma and may also exacerbate hyperoxia-
induced alveolar injury [42]. This eﬀect may explain in part
the failure of Pcp treatment in many patients.
As discussed above, NF-κBa c t i v a t i o ni si n v o l v e di n
both epithelial and macrophage response to Pneumocystis
infection. NF-κB might facilitate the generation of a suc-
cessful immune response and prevent the onset of Pcp
in immunocompetent hosts, while serving to promote
and/or amplify immune-mediated mechanisms of lung
injury during Pcp [35, 36]. NF-κB is an interesting target
fortherapeuticmodulationofimmune-mediatedlunginjury
during Pcp, as it is involved in the generation of both
innate and adaptive immune responses. Speciﬁc blockade
of NF-κB, or certain related signaling kinases, could reduce
the pathological immune response associated with Pcp
and could improve outcome for patients [32]. SSZ is a
potent anti-inﬂammatory drug commonly used to treat the
inﬂammatory consequences of inﬂammatory bowel disease
and rheumatoid arthritis [43–45]. SSZ modulates immune
responses by altering macrophage and T cell responses [46–
48]. Many eﬀects of SSZ are related to its function as a potent
inhibitor of NF-κB, a signaling pathway that is important for
initiating inﬂammatory responses to Pneumocystis [49, 50].
SSZ was highly eﬀective for attenuating the lung inﬂam-
matory response during Pcp. SSZ-treated mice had reduced
immune cell recruitment, reduced cytokine and chemokine
production in the lung, less histological evidence of lung
disease,betterpulmonaryfunction,andgreatersurvivalrates
than untreated mice with Pcp [32]. As noted above, these
data suggest that blockade of the NF-κB signaling pathway
with agents like SSZ can attenuate the inﬂammatory aspects
of Pcp, and may warrant further exploration as a viable
therapeutic target for the treatment of patients.
Other signaling pathways such as mitogen-activated
protein kinase (MAPK) have also been shown to contribute
to the inﬂammatory response to Pneumocystis.W ef o u n d
that the JNK pathway mediates MCP-1 production by
Pneumocystis-stimulated primary murine AEC cultures [37].
In addition, Carmona et al. detected ERK and P38 activation
in human AECs following exposure to Pneumocystis β-
glucan [34]. Blockade of JNK can inhibit proinﬂammatory
gene expression on CD8+ T cells and induce apoptosis of
CD4+ T cells from multiple sclerosis reveals disease patients
[51]. Therefore, targeting speciﬁc MAPK signaling pathways
could also eﬀectively reduce the inﬂammatory consequences
of Pcp.
2.1. GM-CSF. Granulocyte-macrophage colony stimulating
factor (GM-CSF) is a growth factor important for monocyte
and macrophage proliferation, diﬀerentiation, and activa-
tion. GM-CSF plays an important role in host defense
[52, 53], and Mandujano et al. showed that GM-CSF
signiﬁcantly decreased the intensity of Pcp infection in a
CD4+-T-cell-depleted mouse model. This eﬀect is associated
with an enhanced TNF-α production in AMs [54]. In a
later study by Paine et al., CD4-depleted GM-CSF-deﬁcient
mice developed more intense infection and inﬂammationInterdisciplinary Perspectives on Infectious Diseases 5
compared with wild-type mice [55]. AMs from GM-CSF-
deﬁcient mice demonstrated impaired phagocytic function
and reduced TNF-α production in vitro. GM-CSF has also
been shown to be required for Pneumocystis clearance in
neonatal mice and for in vitro killing of organisms by Tc1
CD8+ T cells [21, 56]. Therefore, GM-CSF enhancement
could be a potential strategy to enhance AM function and
host defense against Pneumocystis.
2.2. TNF-α. TNF-α is a potent proinﬂammatory cytokine
secreted primarily by AMs in the lung. It is critical for the
host defense against Pneumocystis, but it also plays an impor-
tant role in Pcp-related lung injury through the recruitment
and activation of inﬂammatory cells that amplify pulmonary
inﬂammation and lung damage [7, 15, 57]. Wright et al.
found an inverse correlation exists between lung TNF-α
levels and pulmonary function in mice with Pcp. Further-
more, the severity of Pcp is also dramatically attenuated in
TNF-α receptor knockout mice [57]. However, inhibition of
TNF-α delayed Pneumocystis clearance in normal mice [58],
and neutralization of TNF-α in immune-reconstituted Pneu-
mocystis-infected SCID mice prevented organism clearance
[59]. Therefore, any therapeutic regiments that block TNF-
α signaling to reduce inﬂammation and lung injury would
need to be combined with anti-Pneumocystis antibiotics to
counteract the negative eﬀects on host defense.
Research to date on host immune responses to Pneumo-
cystis infection has revealed some aspects of the mechanisms
utilized by immune cells that contribute to the pathogenesis
of Pcp-associated lung injury. The extensive interaction
between the immune response and Pneumocystis organisms
suggests that speciﬁc immune modulation could be an
eﬀective therapeutic strategy to treat Pcp patients. A better
understanding of the pathogenesis of this disease may lead
to improved outcomes in patients with Pcp identifying more
eﬃcient and more speciﬁc immunomodulation therapies.
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